The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug last month and lower-than-expected sales figures from Eli Lilly for two ...

The patients had no weight loss plateau and up to 99 per cent of them lost more than 5 per cent of their body weight. More recently, Metsera announced the Phase IIa results for its MET-097i candidate.

The solution?: Lose weight. But the report, published in the journal The Lancet Diabetes & Endocrinology on Tuesday, suggested that having obesity according to the BMI scale doesn't mean a person ...

减肥药研发公司Metsera在上周五向美国证券交易委员会(SEC)提交了首次公开募股(IPO)申请，旨在筹集1亿美元资金。该公司计划在纳斯达克上市，股票代码定为“MTSR”。Metsera专注于治疗肥胖及代谢疾病，致力于开发下一代可注射和口服营养刺激激素(NuSH)类似肽 ...

Other newcomers to the weight-loss drug field include Kailera Therapeutics, which launched in October with $400 million in funding, and Metsera, which debuted in April with $290 million and has ...